255 related articles for article (PubMed ID: 25145430)
21. Use and costs of originator and biosimilar erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia: real-world evidence from an Italian hospital.
Santoleri F; Romagnoli A; Costantini A
Future Oncol; 2019 Jan; 15(1):45-51. PubMed ID: 30468397
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective.
Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R
J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
24. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
[TBL] [Abstract][Full Text] [Related]
25. Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.
Longfield V; Gebhart B; Hayward L
J Support Oncol; 2005; 3(6 Suppl 4):8-9. PubMed ID: 16355548
[No Abstract] [Full Text] [Related]
26. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
Shah HH; Fishbane S
Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257
[TBL] [Abstract][Full Text] [Related]
27. Epoetin alfa and darbepoetin alfa go head to head.
Steensma DP; Loprinzi CL
J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
[No Abstract] [Full Text] [Related]
28. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
Spaepen E; Demarteau N; Van Belle S; Annemans L
Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
[TBL] [Abstract][Full Text] [Related]
29. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
30. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.
McBride A; Balu S; Campbell K; Bikkina M; MacDonald K; Abraham I
Future Oncol; 2017 Oct; 13(25):2285-2295. PubMed ID: 28870106
[TBL] [Abstract][Full Text] [Related]
31. Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients.
McBride A; Alrawashdh N; MacDonald K; Abraham I
Future Oncol; 2022 Jan; 18(3):363-373. PubMed ID: 34747185
[TBL] [Abstract][Full Text] [Related]
32. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer.
Aapro M; Cornes P; Sun D; Abraham I
Ther Adv Med Oncol; 2012 May; 4(3):95-105. PubMed ID: 22590483
[TBL] [Abstract][Full Text] [Related]
33. Epoetin biosimilars in Europe: five years on.
Mikhail A; Farouk M
Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
[TBL] [Abstract][Full Text] [Related]
34. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
35. Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countries.
Duran A; Spaepen E; Lamotte M; Walter E; Umuhire D; Lucioni C; Pinheiro B; Brosa M; Kutikova L; Pujol B; Van Belle S; Annemans L
J Med Econ; 2012; 15(3):409-18. PubMed ID: 22208527
[TBL] [Abstract][Full Text] [Related]
36. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of subcutaneous epoetin-zeta on anemia in renal transplant recipients: a single-center experience.
Sabbatini M; Vitale S; Garofalo G; Torino M; Gallo R; Carrano R; Federico S
Transplant Proc; 2014 Sep; 46(7):2238-40. PubMed ID: 25242760
[TBL] [Abstract][Full Text] [Related]
38. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.
Yousef CC; Khan MA; Almodaimegh H; Alshamrani M; Al-Foheidi M; AlAbdalkarim H; AlJedai A; Naeem A; Abraham I
J Med Econ; 2023; 26(1):394-402. PubMed ID: 36815700
[TBL] [Abstract][Full Text] [Related]
39. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
Cesarec A; Likić R
Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
[TBL] [Abstract][Full Text] [Related]
40. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
Ben-Hamadi R; Duh MS; Aggarwal J; Henckler A; McKenzie RS; Tak Piech C
Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]